Although there are currently limited studies on GLUT3-targeted anti-tumor therapy, its higher affinity for glucose, relatively specific distribution in tumor cells, and greater sensitivity to tumors in a low-glucose microenvironment (such as the necrotic area) endow GLUT3-targeted anti-tumor therapy with a more promising therapeutic prospect, especially for glioblastoma, brain metastases, and chemotherapy-resistant tumors
doi: 10.3390/ijms24044004 167 XiongJChenXZhaoZLiaoYZhouTXiangQJEet al
E.MontineT
Amylin, a peptide hormone co-secreted with insulin, has long been recognized as a target for weight and glycemic control due to its role in regulating satiety, gastric emptying, and postprandial glucagon secretion
The Phase II trials studied a topical ophthalmic solution of full-length T4 for dry eye, and even there the results were mixed on the primary endpoints
2025;38(2):e15702